IQVIA (IQV) Q4 2025 earnings review
Top-Line Acceleration Masks Margin Compression
IQVIA closed 2025 with its strongest growth of the year, delivering 10.3% reported revenue growth to $4.36B, comfortably beating the high end of its prior guidance ($4.30B). The R&D Solutions (R&DS) engine has fully reignited with a 1.18x book-to-bill ratio and $2.7B in bookings. However, profitability quality is a concern: while revenue surged 10%, Adjusted EBITDA only grew 5%, causing margins to compress by ~110 basis points YoY. Management initiated a significant segment restructuring for 2026, merging CSMS into TAS, which complicates historical comparisons just as the legacy TAS business stabilizes.
🐂 Bull Case
The slump is over. R&DS bookings hit a year-high $2.7B with a 1.18x book-to-bill, driving backlog to a record $32.7B (+5.3% YoY). The segment accelerated to 9.9% revenue growth, proving the 'See More, Win More' strategy is taking share.
Free Cash Flow conversion remains elite. IQVIA generated $2.05B in FCF for FY25, representing 99% of Adjusted Net Income. This fuels the $1.2B annual buyback pace and deleveraging capabilities.
🐻 Bear Case
Operating leverage is moving in the wrong direction. Adjusted EBITDA margin compressed from 25.1% in Q4 2024 to 24.0% in Q4 2025. Costs (COGS + SG&A) are growing faster than revenue.
Net leverage ticked up to 3.63x Adjusted EBITDA, compared to 3.52x in Q3 and 3.33x a year ago. With interest expense rising to $729M annually (+8.8%), the balance sheet is becoming a heavier drag on GAAP earnings.
⚖️ Verdict: 🟢
Solid. The top-line acceleration is undeniable, and the R&DS bookings recovery validates the bull thesis on demand. However, the margin compression prevents a perfect score. The 2026 segment shuffle warrants scrutiny to ensure it isn't masking weakness in the commercial tech stack.
Key Themes
R&DS Bookings Acceleration
Accelerating. The clinical trial business has definitively turned the corner. Book-to-bill improved sequentially throughout 2025 (1.02 -> 1.12 -> 1.15 -> 1.18). Q4 bookings of $2.7B are the highest of the year, securing $8.3B in revenue conversion for the next 12 months.
EBITDA Margin Compression
Margins contracted significantly in Q4. While revenue grew 10.3%, Adjusted EBITDA only grew 5.0%. The implied Q4 Adjusted EBITDA margin fell to roughly 24.0% from 25.1% a year prior. Management cited 'investments in AI innovations' and operational discipline, but the data shows expense lines (Cost of Revenue +13.5%) outpacing sales.
Segment Reporting Overhaul
Effective Jan 1, 2026, the fast-growing CSMS segment (+18.6% growth) is being merged into TAS (renamed 'Commercial Solutions'). While management claims operational alignment, this reduces transparency by blending the volatile contract sales business with the recurring-revenue tech/data business, potentially obscuring organic growth trends in the core tech stack.
TAS & CSMS Outperformance
Accelerating. Technology & Analytics Solutions (TAS) grew 9.8% reported (up from 5.0% in Q3), and Contract Sales (CSMS) surged 18.6%. Both segments outperformed expectations, driven by 'expanded go-to-market strategy' and new drug launch support.
Rising Debt Load
Net leverage has crept up to 3.63x (from 3.33x in 24Q4). Interest expense for the quarter was $193M, up 12.8% YoY. 2026 guidance explicitly notes a further step-up in interest expense of ~$80M due to refinancing and annualization of 2025 financing activities.
Other KPIs
Accelerating. Up 9.6% YoY, improving from the 6-7% growth rates seen earlier in the year. Beat the high end of the guidance range ($3.45), driven by revenue outperformance rather than margin expansion.
Stable. Represents 99% of Adjusted Net Income. While slightly down from FY24 ($2,114M), conversion remains high. Management continues to deploy this into buybacks ($1.24B in 2025) despite rising leverage.
Stable Growth. Up 5.3% YoY. The conversion engine is steady, with ~25% of the backlog ($8.3B) expected to convert to revenue in the next 12 months.
Guidance
Decelerating vs Q4. The midpoint ($17.25B) implies ~5.8% YoY growth. While solid, this is a deceleration from the 10.3% sprint seen in Q4 25, suggesting management remains cautious about sustaining double-digit growth rates.
Stable. Midpoint ($4.0B) implies ~5.6% growth, roughly in line with revenue growth. This indicates management does not expect meaningful margin expansion in 2026, likely due to the noted step-up in interest expenses and ongoing AI investments.
Stable. Midpoint ($12.70) implies ~6.5% growth. This aligns with the long-term algorithm but lacks upside surprise given the increased interest expense headwinds ($80M step-up).
Key Questions
EBITDA Margin Compression
Adjusted EBITDA margins compressed ~110bps YoY in Q4 despite strong 10% revenue growth. Is this purely mix-driven (CSMS/Passthroughs), or are core operating costs rising faster than pricing power allows?
Segment Transparency
With the merger of CSMS into TAS, how should investors track the organic growth of the core technology/data business versus the lower-margin, more volatile contract sales business?
Deleveraging Plan
Net leverage is at 3.63x and interest expense is guiding up significantly for 2026. At what point does debt paydown take priority over share buybacks ($1.2B in '25)?